Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.095 USD | -0.91% | -2.68% | +5.60% |
20/05 | Barclays Adjusts Price Target on GoodRx to $10 From $9, Maintains Overweight Rating | MT |
17/05 | UBS Adjusts Price Target on GoodRx Holdings to $9 From $8, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.60% | 2.69B | |
+30.93% | 456B | |
+32.09% | 280B | |
+6.37% | 134B | |
+29.89% | 94.31B | |
+5.27% | 91.48B | |
+59.54% | 60.48B | |
+13.77% | 46.13B | |
+25.91% | 37.31B | |
-0.16% | 35.48B |
- Stock Market
- Equities
- GDRX Stock
- News GoodRx Holdings, Inc.
- Goldman Sachs Trims Price Target on GoodRx Holdings to $6 From $7, Maintains Neutral Rating